Tumor microvasculature tends to be malformed, more permeable, and more tortuous than vessels in healthy tissue, effects that have been largely attributed to up-regulated VEGF expression. However, tumor tissue tends to stiffen during solid tumor progression, and tissue stiffness is known to alter cell behaviors including proliferation, migration, and cell-cell adhesion, which are all requisite for angiogenesis. Using in vitro, in vivo, and ex ovo models, we investigated the effects of matrix stiffness on vessel growth and integrity during angiogenesis. Our data indicate that angiogenic outgrowth, invasion, and neovessel branching increase with matrix cross-linking. These effects are caused by increased matrix stiffness independent of matrix density, because increased matrix density results in decreased angiogenesis. Notably, matrix stiffness up-regulates matrix metalloproteinase (MMP) activity, and inhibiting MMPs significantly reduces angiogenic outgrowth in stiffer crosslinked gels. To investigate the functional significance of altered endothelial cell behavior in response to matrix stiffness, we measured endothelial cell barrier function on substrates mimicking the stiffness of healthy and tumor tissue. Our data indicate that barrier function is impaired and the localization of vascular endothelial cadherin is altered as function of matrix stiffness. These results demonstrate that matrix stiffness, separately from matrix density, can alter vascular growth and integrity, mimicking the changes that exist in tumor vasculature. These data suggest that therapeutically targeting tumor stiffness or the endothelial cell response to tumor stiffening may help restore vessel structure, minimize metastasis, and aid in drug delivery.
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tumor stiffness | endothelial cells | vascular permeability | glycation | extracellular matrix T he ingrowth of newly sprouted blood vessels is necessary for solid tumor growth, and tumor vasculature is typically malformed, leakier, and more tortuous than the vasculature of normal tissues (1) (2) (3) . Generally, aberrant tumor vasculature is considered to be caused by up-regulated VEGF expression resulting in chaotic vascular growth and failure to establish mature, well-regulated networks (4, 5) . Here, we propose a different hypothesis, namely that extracellular matrix (ECM) mechanical properties also contribute to the aberrant vascular phenotype seen in tumors.
Solid tumor tissue is typically stiffer than native, healthy tissue (1, 6) . Increased ECM stiffness within tumors is caused primarily by both increased collagen deposition and increased cross-linking within the tumor stroma (7) . Increased ECM density and crosslinking are associated with poor prognosis in a number of cancers (8, 9) . Many studies have investigated the role of matrix density on angiogenesis and, in both collagen and fibrin matrices, have shown that angiogenesis decreases with increasing matrix concentration (10) (11) (12) (13) . Increased matrix density appears to act as a physical barrier that restricts cell migration, and cells rely on matrix metalloproteinases (MMPs) to overcome that barrier (14, 15) . Indeed, evidence points to an important role of MMP regulation in efficient angiogenesis (16, 17) . Most notably, membrane-type matrix metalloproteinase 1 (MT1-MMP) appears to play a central role in regulating tumorassociated angiogenesis and vascular function (18) . However, within the tumor microenvironment, ECM stiffness can increase independently of collagen density through cross-linking enzymes (7). Cross-linking can result in increased matrix stiffness without changing the ECM architecture (19) . Recent work has shown that endothelial cells (ECs) are mechanosensitive to changes in matrix stiffness (20, 21) , but matrix stiffening in the tumor microenvironment affects tumor angiogenesis remains less clear.
In this study, we examine the effects of collagen cross-linking and the resulting increase in matrix stiffness on the growth and integrity of angiogenic vessels. Using in vitro, in vivo, and ex ovo models, we show that increasing the extent of collagen crosslinking leads to significantly more vessel outgrowth and branching. We further show that matrix stiffness plays an important role in vessel permeability and endothelial cell-cell junctional integrity. Together, our results demonstrate that matrix cross-linking modulates the growth, structure, and integrity of neo-vessels and suggest that the phenotype of tumor vasculature is mediated in part by collagen cross-linking.
Significance
Dysregulation of both vascular architecture and function is a hallmark of numerous diseases, including cancer. This dysregulation is currently largely attributed to up-regulated proangiogenic growth factors. Here, we show that the stiffness of the underlying extracellular matrix also plays a central role in promoting angiogenesis and a characteristic tumor-like vasculature both in vitro and in vivo. The matrix stiffness-mediated angiogenesis is dependent on increased matrix metalloprotease activity. In addition, increased matrix cross-linking disrupts endothelial cell-cell junctional integrity and results in leakier vasculature. These results suggest that altered tissue mechanics, which are characteristic of solid tumors, directly influence vascular phenotype and, subsequently, may impair therapeutic delivery and efficacy.
Results
Collagen Cross-Linking and Collagen Density Modulate the Mechanical Properties and Fiber Arrangements of Collagen Gels. To establish an in vitro model in which collagen stiffness can be modulated, the individual and combined effects of collagen cross-linking and collagen density on the mechanical and structural properties of collagen gels were studied. Cross-linking of collagen was done through nonenzymatic glycation to form advanced glycation end product (AGE) cross-links (19), followed by confined compression testing to characterize the mechanical properties of the collagen gels. Increasing the density of the collagen gels from 1.5 to 10 mg/mL increases the equilibrium compressive modulus approximately sixfold, from ∼180 to ∼1,200 Pa (Fig. 1A) . Within a given density, increasing the extent of glycation from 0 to 100 mM also increases the modulus of the gels from ∼180 to ∼500 Pa, ∼600 to ∼715 Pa, and ∼1,200 to ∼1,400 Pa for 1.5-, 5-, and 10-mg/mL collagen gels, respectively. To investigate the effects of collagen density and cross-linking on collagen gel fiber architecture further, the internal collagen fiber distributions were visualized with confocal reflectance microscopy. Increasing the density of the collagen visibly decreases the porosity and alters the size and distribution of fibers within the collagen gels (Fig. S1 ). However, collagen gels within a given density and glycated with 0, 50, or 100 mM ribose form gels with qualitatively similar fiber architectures. Taken together, these results indicate that nonenzymatic glycation can modulate the mechanical properties of collagen gels while only minimally altering the collagen fiber architecture.
Angiogenic Outgrowth and Branching Are Modulated by ECM Mechanical
Properties. The effects of stiffening collagen gels via either crosslinking through glycation or increased density on EC migration and outgrowth were investigated. Interestingly, single-cell 3D migration speed decreased and the persistence time increased as the stiffness of the gels increased ( Fig. 1 B and C) . Increasing the density of the collagen matrix decreased the overall outgrowth of angiogenic sprouts from the spheroids (Fig. S2) , as has been shown previously (11) . Importantly, however, at all densities, increasing the stiffness of the collagen via glycation increased the outgrowth response from the spheroids. EC spheroids invaded significantly farther in collagen gels glycated with 100 mM ribose than with 0 mM ribose beginning at days 1 and 3 for 1.5-mg/mL and 5-mg/mL collagen densities, respectively (Fig. 1D ). This trend is observed across all collagen densities, although it is not statistically significant at 10 mg/mL. However, there were significantly more angiogenic sprouts in glycated gels at all densities (Fig. 1E ). These findings suggest that the effects of stiffness on EC sprouting are dependent on the mechanism of stiffening, i.e., cross-linking or increased density.
Notably, tumor angiogenesis is marked by increased branching and tortuosity (5). Our previous work indicates that matrix crosslinking alters the shape of individual cells (19) , suggesting it also may alter the shape of assemblies of cells during angiogenesis. To analyze further the effects of matrix stiffness on the shape and structure of neovessels, the density of branching along vessels outgrowths was analyzed. Increasing the stiffness of the gels via nonenzymatic glycation increased the density of branching in angiogenic outgrowths from spheroids ( Fig. 2A) . Outgrowths from spheroids in stiffer gels (100 mM ribose) had an ∼1.5-fold increase in branching compared with those within more compliant (0 mM ribose) gels (Fig. 2B ). These findings indicate that increasing matrix stiffness via cross-linking not only causes increased outgrowth from spheroids but also changes the morphology of the angiogenic sprouts that form, mimicking the changes occurring in the tumor microenvironment.
Given our in vitro findings, we speculated that tumor angiogenesis is mediated in part by the matrix cross-linking that occurs in the tumor microenvironment. To investigate the relationship between tissue stiffness and tumor angiogenesis, we extended our analysis to the MMTV-PyMT mouse tumor model (6, 22) . To modulate the stiffness of the spontaneous mammary tumors that develop in these mice, we used β-aminopropionitrile (BAPN), an inhibitor of the matrix cross-linking enzyme lysyl oxidase (LOX) involved in tumor stiffening ( Fig. 2C) (6, 23) . BAPN is a commonly used model to interrogate the mechanical properties of the ECM EC multicellular spheroids were embedded within 1.5-mg/mL collagen gels glycated with 0, 50, or 100 mM ribose. (A) Spheroids were fixed, stained for actin (green) and nuclei (blue), and imaged using confocal microscopy after 5 d. (Scale bar, 100 μm.) (B) The number of branches per sprout length was counted, and data were normalized to the 0-mM ribose condition. AU, arbitrary units. (C) MMTV-PyMT mice were treated with BAPN to prevent collagen cross-linking or with vehicle (controls; Ctrl), and the equilibrium compressive moduli were measured using unconfined compression testing. (D) The tumor vasculature was visualized using ultrasound. (E) The number of visible vascular branches was quantified using the ImageJ Tubeness plugin. Data are presented as mean + SEM; *P < 0.05.
in tumor physiology and enables the examination of the effects of matrix cross-linking on angiogenesis when cross-linking is modulated by inhibition of LOX (6, 22) . Ultrasound power wave Doppler was used to image the extensive vasculature within PyMT mouse tumors (Fig. 2D, Fig. S3A and Movie S1). The vasculature in BAPN-treated mice, in which tumor stiffness is decreased, was far less prominent (Fig. 2D, Fig. S3A , and Movie S2). Quantification of the vascular network indicates that the number of branches and junctional nodes within the vascular network is significantly reduced in mice treated with BAPN compared with the vehicle control treatment (Fig. 2E and Fig. S3B ). Overall, reducing tumor stiffness by decreasing collagen cross-linking with BAPN reduced the extent of angiogenesis within the tumor.
Given our in vivo results showing increased angiogenesis in crosslinked matrices, we extended our analysis to an ex ovo chick chorioallantoic membrane (CAM) angiogenesis assay. Collagen implants containing 5 μg/mL VEGF were placed on the distal region of the CAM on embryonic day (E) 10 (Fig. S4A) . A VEGF ELISA was used to examine the release profile of VEGF to confirm that VEGF release is not affected by the stiffness of the gels (Fig. S4B) . On E15, vessels within the collagen gels were imaged using confocal microscopy and appeared as thin fluorescent sprouts (Fig. 3A, arrowheads) . Stiffer collagen gels (100 mM ribose) promoted significantly more angiogenesis than the more compliant (0 mM ribose) gels (Fig. 3B) . These data support our in vitro and in vivo findings that matrix stiffness resulting from cross-linking enhances angiogenesis.
Stiffness-Mediated Angiogenic Outgrowth Requires MMP Activity.
Because prior work suggests that MMP activity plays a key role in cell migration in response to increased matrix density (11, 15) , we hypothesized it may serve a similar function in mediating angiogenesis in response to increased matrix cross-linking. Toward that end, we assayed for the expression and activity of the MT1-MMP in ECs in 3D cell culture because of its role in regulating tumor vasculature (18) . Both MT1-MMP expression and activity, as revealed by the presence of the cleaved fragment, were increased in the stiffer gels (100 mM ribose) compared with the more compliant gels (0 mM ribose) (Fig. 4A) . Treatment with the MMP inhibitor GM6001 blocked MT1-MMP cleavage in both conditions. Using a specific MT1-MMP activity probe, we confirmed that MT1-MMP activity was indeed increased in stiffer gels (Fig. 4B ). Similar to observations in epithelial cells (24) , the stiffness-mediated increase in EC MT1-MMP activity is dependent on Rho-associated protein kinase (ROCK)-mediated cell contractility (Fig. 4B) . However, we did not observe any significant changes in MT1-MMP mRNA content in the gels of different stiffness (Fig. 4C) or any significant differences in content in vivo (Fig. S5) . We then examined spheroid outgrowth when MMPs were inhibited using GM6001. Spheroids in stiffer gels (100 mM ribose) had significantly less angiogenic outgrowth in the presence of 5 μM GM6001 than did untreated control cells in the same matrix (Fig. 4 B and C) ; the spheroid outgrowth was similar within the more compliant gels (0 mM ribose) with or without GM6001 treatment. In all conditions, the morphologies of angiogenic sprouts were altered with GM6001 treatment (Fig. 4D) . Sprouts in compliant and stiff control gels (0 and 100 mM ribose) had similar morphologies, whereas sprouts from spheroids cultured with GM6001 were much thinner than controls (Fig. 4E) . Moreover, stiffness-mediated angiogenic outgrowth in the CAM angiogenesis assay was prevented upon MMP inhibition (Fig. 4F) . These data suggest that MMPs play an important role in promoting the increased angiogenesis observed in stiffer matrices.
Matrix Stiffness Influences the Localization of Vascular Endothelial
Cadherin and Barrier Integrity. We next sought to investigate the functional integrity of newly formed vessels as a function of matrix stiffness. Importantly, increased vessel permeability is a hallmark of EC multicellular spheroids were embedded within 1.5-mg/mL collagen gels glycated with 0 or 100 mM ribose and fed with complete medium with (GM6) or without (Ctrl) 5 μM GM6001. (Scale bar, 200 μm.) (E) Spheroid outgrowth was quantified after 3 d of culture and normalized to the day 0 condition. (F) Spheroids were stained for actin (green) and nuclei (blue) and were imaged with confocal microscopy. (Scale bar, 100 μm.) (G) The width of angiogenic sprouts was measured by fitting the intensity profile of a line drawn perpendicular to the sprout with a two-Gaussian curve. (H) Quantification of vessel density into 1.5-mg/mL collagen gels glycated with 0 or 100 mM ribose during the CAM angiogenic sprouting assay with or without 5 μM GM6001. Data are presented as mean + SEM; *P < 0.05. tumor vasculature (2, 25) . Our previous data indicate that increased matrix stiffness disrupts cell-cell junctions (20, 21, 26) , suggesting that stiffness may result in impaired barrier integrity. Vascular endothelial cadherin (VE-cadherin) within EC-EC junctions in vascular sprouts was imaged as a function of stiffness (Fig. 5A) . We found that the VE-cadherin junctions within the stiff (100 mM ribose) collagen were significantly wider than those within the more compliant (0 or 50 mM ribose) collagen gels (Fig. 5B) .
Our previous data suggest that subconfluent ECs on compliant substrates assemble spontaneously into networks reminiscent of the angiogenic process (27) . Using this 2D platform, which is more amenable to imaging and manipulation than 3D cultures, we extended our analysis of VE-cadherin to EC cultured on compliant (0.2 kPa) or stiff (10 kPa) polyacrylamide (PA) substrates to visualize and characterize its localization better. Cells on compliant substrates formed VE-cadherin-and β-cateninpositive EC-EC junctions that were continuous between cells, whereas the junctions on stiff substrates were punctate (Fig. 5C) . The tight junction protein zona occuldens 1 (ZO-1) shows stiffness-mediated localization that matches with VE-cadherin localization (Fig. S6A) . In vivo staining of VE-cadherin, ZO-1, and β-catenin further revealed changes in junction architecture in stiffer tumors (Fig. S6 B and C) . Cytoskeletal fractionation of cell lysate from ECs indicates that significantly greater proportions of total VE-cadherin, β-catenin, and γ-catenin content were found in the Triton-insoluble fraction in ECs plated on compliant gels than in ECs plated on the gels (Fig. 5D ). Junction proteins of ECs embedded within glycated 3D collagen gels presented a similar stiffness-mediated insoluble/soluble dependence (Fig. 5E) .
We further proceeded to investigate the effects of matrix stiffness and altered VE-cadherin localization on ECs barrier integrity. Because AGEs are found in tumors (28, 29) and have been shown before to perturb EC barrier integrity (30), we proceeded to evaluate the permeability of EC monolayers on glycated collagen-coated PA gels of varying stiffness. Although increasing the matrix stiffness significantly increased the permeability of EC monolayers, the extent of collagen glycation had no significant effect (Fig. 5 F and G) , suggesting that increased permeability is caused by matrix stiffness, not by EC interaction with AGEs. Moreover, we observed an increase in vessel permeability as a function of stiffness using the CAM angiogenesis assay (Fig. 5H) . We then extended our analysis to the BAPN-treated MMTVPyMT mouse tumor model, using an in vivo Evans blue extravasation assay to confirm our in vitro permeability findings. Notably, the higher matrix stiffness found in control mice disrupts EC barrier function of the tumor-associated vasculature to a greater extent than in the BAPN-treated mice (Fig. 5 I and J and Fig. S7 ). Of note, we did not observe any BAPN-mediated effects on EC permeability or mRNA expression in vitro, suggesting that BAPN does not affect EC integrity directly (Fig. S8) . Together, these data indicate that the stiffness of the matrix modulates the integrity of VE-cadherin junctions, with stiff substrates preventing strong cellcell adhesion and disrupting barrier integrity.
Discussion
Matrix cross-linking is one of the main mechanisms by which the tumor stroma stiffens during solid tumor progression (6, 7). Although several studies have investigated the role of increasing 3D matrix stiffness via matrix density on angiogenesis (10-13), much less is known about the role of cross-linking on the formation of vascular structures. Here, we modulated matrix stiffness by increasing the extent of cross-linking through nonenzymatic glycation. We show that increasing matrix cross-linking increased the extent of outgrowth and branching in endothelial spheroids, in vivo mouse tumors, and in an ex ovo embryonic chick model. We demonstrate that endothelial cell-cell junctional properties are modulated by the stiffness of the matrix and that the localization of VE-cadherin and the permeability of endothelial monolayers are significantly altered by matrix stiffness. We also show that inhibiting MMP activity prevents the increased outgrowth from spheroids in cross-linked matrices and alters the resultant angiogenic sprout morphology. Together, these results show that 3D matrix stiffness plays an important role in regulating angiogenesis and vascular stability.
The vasculature within tumors is known to have disrupted cellcell junctions and to be more permeable than the vasculature in normal tissues (2) . Notably, both our current and previous work indicate that matrix stiffness can disrupt VE-cadherin cell-cell junctions and increase vessels' leakiness (20) . Interestingly, strong VE-cadherin cell-cell interaction can prevent sprouting (31) . In addition, differential VE-cadherin dynamics between cell-cell junctions are required for vascular morphogenesis (32) . Expression of the cytoplasmic tail of VE-cadherin can induce endothelial membrane protrusions in a process that depends on its subcellular localization (33) . Taken together, these observations highlight a possible links among matrix stiffness, VE-cadherin localization, vessel leakiness, and sprouting dynamics.
Increased matrix density is known to act as a barrier to cell migration (13, 14) , and any effect from increased stiffness caused by increased density cannot be decoupled from the altered matrix architecture. Others have demonstrated transient, decreased sprouting responses in matrices glycated with glucose-6-phospate but also noted increased branching and tortuosity (34, 35) . Of note, direct exposure to high concentrations of glucose is known to affect cells adversely (36) , whereas AGEs can have direct antiangiogenic effects on ECs (37, 38) . Interestingly, it has been suggested that AGEs could contribute to ECM stiffening in tumors (29) . In our experiments, increasing the collagen matrix stiffness via a preglycation step results in more angiogenic sprouting in vitro and ex ovo. Moreover, inhibition of the cross-linking in tumors in vivo resulted in reduced vasculature density and permeability. Such findings are consistent with the decreased rate of metastasis observed in BAPN-treated mice (39) , suggesting lower vasculature density and permeability could reduce the ability of tumor cells to enter the blood stream. Furthermore, alternative methods of increasing collagen matrix stiffness, such as the use of microbial transglutaminase or varying the ratio of collagen monomers to oligomers, support our findings of increased angiogenic outgrowth in stiffer matrices (40, 41) . Overall, when combined with our data showing the absence of increased endothelial permeability strictly resulting from collagen glycation, these findings indicate that matrix stiffness acts as an important regulator of the vascular phenotype.
Previously published work has shown that MMP activity is an important regulator of angiogenesis (10, 42, 43) . GM6001 is a broad-spectrum MMP inhibitor that is known to inhibit the degradation of collagen by MMPs and, interestingly, has been shown to reduce the formation of angiogenic structures in response to the matrix density of fibrin gels (10) . Prior studies have seen differences in the angiogenic sprouting response following extended incubation times (3-21 d) with different GM6001 concentrations and collagen matrix density (10, 42, 43) . Similarly, we demonstrate that MMP activity is essential for the increased angiogenic response we observed within the stiffer, cross-linked collagen gels. Importantly, both the amount of active cleaved fragment of MT1-MMP and the total content were significantly higher in stiffer matrix. The GM6001 treatment resulted in a small decrease in angiogenic sprouting (along with dramatic changes in the sprout morphology) after 3 d of culture in the compliant collagen gels, whereas GM6001 treatment completely blocked the stiffnessmediated angiogenesis in the ex ovo CAM model. Taken together, these data show that MMPs are integral to the formation of angiogenic sprouts occurring in stiffer matrix.
Antiangiogenic therapies targeting VEGF are currently in therapeutic use and do provide some benefit (3, 44) . However, although such therapeutics strategies are effective on a short time scale, they do not completely block the angiogenic process or provide sustained long-term normalization of the tumor vasculature (3, 45) . Interestingly, these treatments induce severe tumor hypoxia (46) . In turn, hypoxia has been shown to promote ECM remodeling and the expression of cross-linking proteins such as LOX (47, 48) . Therefore, our current results provide a potential explanation for why increasing matrix stiffness promotes tumor revascularization. Increased matrix stiffness has been shown to potentiate cell responses to several different soluble factors present in the tumor microenvironment (49) (50) (51) , and in some cases increased matrix stiffness can change the signaling pathways triggered by soluble factors (50) . Thus it is possible that the interplay between matrix stiffness and soluble factors might induce or even worsen the tumor-like vascular phenotype. Overall, a combined therapeutics strategy that includes targeting matrix stiffness or the cellular response to stiffness is likely to improve the outcome of primary treatments targeting angiogenic factors or other soluble factors.
Overall, increasing matrix stiffness promotes a tumor-like vascular phenotype, most notably by disrupting vessel architecture and integrity and promoting outgrowth. The altered vascular phenotype promoted by altered stiffness most likely involves the interplay between cell contractility and matrix stiffness. Notably, similar to our findings in ECs, activation of MT1-MMP in epithelial cells depends on both matrix stiffness and cell contractility (24) . In addition, both the angiogenic process and tumor permeability are regulated by VEGF receptors, which in turn are known to be transactivated by integrin receptors (52, 53) . Interestingly, alternative splicing of protein isoforms, including VEGF and proangiogenic signaling proteins, is regulated by matrix stiffness (22) . Therefore, our results show that a further understanding of the underlying mechanism governing the relationship between matrix stiffness and tumor vascular phenotype is needed to design therapeutics targeting either tumor stiffness or the EC response to tumor stiffening.
Materials and Methods
All mice were maintained following a protocol approved by the Cornell University Institutional Animal Care and Use Committee. A detailed description of the protocols used in this study, including mice and chicks studies, cell culture, spheroid generation and studies, Western blotting, immunofluorescence, permeability assays, confocal reflectance imaging, single-cell migration, PA gel synthesis, and the preparation of collagen scaffolds are described in SI Materials and Methods.
